Welcome to our dedicated page for Whitehawk Therapeutics SEC filings (Ticker: WHWK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Whitehawk is a clinical-stage oncology therapeutics company focused on antibody-drug conjugate (ADC) cancer treatments, and its filings offer insight into financial results, development plans and corporate activities related to this strategy.
Among the key documents available are current reports on Form 8-K, which Whitehawk has used to furnish press releases announcing quarterly financial results and recent highlights. These filings reference information such as research and development spending, progress toward Investigational New Drug (IND) submissions for ADC programs like HWK-007 and HWK-016, and updates on the company’s three-asset ADC portfolio targeting PTK7, MUC16 and SEZ6.
On this page, users can also locate Whitehawk’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more detailed discussions of the company’s oncology pipeline, risk factors, and financial condition. For investors interested in governance and compensation matters, proxy materials and related filings can provide additional context on board and executive oversight of the ADC development strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major updates without having to parse every page. Real-time updates from the SEC’s EDGAR system ensure that new WHWK filings, including future 10-Ks, 10-Qs and 8-Ks, appear promptly. Users can also review insider transaction reports on Form 4, when available, to see reported trades by directors and officers.
Together, these resources give a structured view of how Whitehawk reports its financial performance, clinical progress and corporate decisions to regulators and the market.
In its first quarter post-divestiture, Whitehawk Therapeutics (WHWK) filed a Q2 2025 10-Q showing a markedly stronger balance sheet and a shift to pre-clinical R&D.
Liquidity: Cash, cash equivalents and short-term investments rose to $177.2 M from $47.2 M at YE-24, funded by the $102.4 M sale of FYARRO (closed 25 Mar 25) and a $100 M PIPE (21.6 M shares & 20.1 M pre-funded warrants at $2.40).
Operations: With FYARRO gone, Q2 revenue fell to $0 (vs $6.2 M). R&D expense jumped to $48.8 M (Q2 24: $13.1 M) after paying the remaining $38 M WuXi license fee for three antibody-drug conjugate (ADC) programs. SG&A declined 25 % YoY to $5.9 M. Net loss widened to $52.6 M (-$0.76/sh).
Six-month view: An $87.4 M gain on the FYARRO sale produced $20.4 M net income for 1H 25, yet operating cash burn reached $64.8 M.
- Total assets: $180.8 M; liabilities: $8.8 M; no debt.
- Equity climbed to $172.1 M and shares outstanding to 47.1 M (8 Aug 25).
- Outstanding dilution: 22.1 M pre-funded warrants & 7.6 M options.
Outlook: Management believes current cash funds ≥12 months of accelerated ADC development; future value creation now hinges on advancing these pre-clinical candidates into the clinic.